180 related articles for article (PubMed ID: 27007008)
1. Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):17-8. PubMed ID: 27007008
[No Abstract] [Full Text] [Related]
2. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
3. Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):7-8. PubMed ID: 27007003
[No Abstract] [Full Text] [Related]
4. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
Gautam A; Zhu Y; Ma E; Lee SY; Zagadailov E; Teasell J; Richhariya A; Bonthapally V; Huebner D
Leuk Lymphoma; 2018 Jan; 59(1):69-76. PubMed ID: 28583027
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):20. PubMed ID: 25768999
[No Abstract] [Full Text] [Related]
7. Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):6. PubMed ID: 27007002
[No Abstract] [Full Text] [Related]
8. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martínez C; de Haro ME; Romero S; Gutiérrez A; Domingo-Domènech E; González-Rodríguez AP; Zeberio I; Martínez-Badas MP; Rodríguez-Izquierdo A; Carpio C; Bastos-Oreiro M; Hernández-Rivas JÁ; Vallansot R; Kelleher N; Díaz-Gálvez FJ; Torrado T; Pereira A; García-Sanz R;
Ann Hematol; 2023 Feb; 102(2):429-437. PubMed ID: 36370191
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
Kort J; Chidiac A; El Sayed R; Massoud R; Nehme R; Bazarbachi A; El-Cheikh J
Leuk Lymphoma; 2020 Jul; 61(7):1732-1735. PubMed ID: 32090673
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
16. Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting.
Nademanee A; Sureda A; Stiff P; Holowiecki J; Abidi M; Hunder N; Pecsok M; Uttarwar M; Purevjal I; Sweetenham J
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2354-2359. PubMed ID: 29859255
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.
Hui L; von Keudell G; Wang R; Zeidan AM; Gore SD; Ma X; Davidoff AJ; Huntington SF
Cancer; 2017 Oct; 123(19):3763-3771. PubMed ID: 28640385
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin: axonal microtubule's Apollyon.
Mariotto S; Ferrari S; Sorio M; Benedetti F; Tridente G; Cavallaro T; Gajofatto A; Monaco S
Blood Cancer J; 2015 Aug; 5(8):e343. PubMed ID: 26314985
[No Abstract] [Full Text] [Related]
19. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.
Parker C; Woods B; Eaton J; Ma E; Selby R; Benson E; Engstrom A; Sajosi P; Briggs A; Bonthapally V
J Med Econ; 2017 Jan; 20(1):8-18. PubMed ID: 27472034
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
